151 related articles for article (PubMed ID: 21376342)
1. Opioids protect against substantia nigra cell degeneration under conditions of iron deprivation: a mechanism of possible relevance to the Restless Legs Syndrome (RLS) and Parkinson's disease.
Sun YM; Hoang T; Neubauer JA; Walters AS
J Neurol Sci; 2011 May; 304(1-2):93-101. PubMed ID: 21376342
[TBL] [Abstract][Full Text] [Related]
2. Does the endogenous opiate system play a role in the Restless Legs Syndrome? A pilot post-mortem study.
Walters AS; Ondo WG; Zhu W; Le W
J Neurol Sci; 2009 Apr; 279(1-2):62-5. PubMed ID: 19167016
[TBL] [Abstract][Full Text] [Related]
3. Early signs of neuronal apoptosis in the substantia nigra pars compacta of the progressive neurodegenerative mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/probenecid model of Parkinson's disease.
Novikova L; Garris BL; Garris DR; Lau YS
Neuroscience; 2006 Jun; 140(1):67-76. PubMed ID: 16533572
[TBL] [Abstract][Full Text] [Related]
4. Thy1 expression in the brain is affected by iron and is decreased in Restless Legs Syndrome.
Wang X; Wiesinger J; Beard J; Felt B; Menzies S; Earley C; Allen R; Connor J
J Neurol Sci; 2004 May; 220(1-2):59-66. PubMed ID: 15140607
[TBL] [Abstract][Full Text] [Related]
5. Multiregional brain iron deficiency in restless legs syndrome.
Godau J; Klose U; Di Santo A; Schweitzer K; Berg D
Mov Disord; 2008 Jun; 23(8):1184-7. PubMed ID: 18442125
[TBL] [Abstract][Full Text] [Related]
6. Hyperactivity, dopaminergic abnormalities, iron deficiency and anemia in an in vivo opioid receptors knockout mouse: Implications for the restless legs syndrome.
Lyu S; DeAndrade MP; Mueller S; Oksche A; Walters AS; Li Y
Behav Brain Res; 2019 Nov; 374():112123. PubMed ID: 31376441
[TBL] [Abstract][Full Text] [Related]
7. Puerarin protects dopaminergic neurons against 6-hydroxydopamine neurotoxicity via inhibiting apoptosis and upregulating glial cell line-derived neurotrophic factor in a rat model of Parkinson's disease.
Zhu G; Wang X; Chen Y; Yang S; Cheng H; Wang N; Li Q
Planta Med; 2010 Nov; 76(16):1820-6. PubMed ID: 20509103
[TBL] [Abstract][Full Text] [Related]
8. Altered dopaminergic profile in the putamen and substantia nigra in restless leg syndrome.
Connor JR; Wang XS; Allen RP; Beard JL; Wiesinger JA; Felt BT; Earley CJ
Brain; 2009 Sep; 132(Pt 9):2403-12. PubMed ID: 19467991
[TBL] [Abstract][Full Text] [Related]
9. Clinical characteristics of Restless legs syndrome in patients with Parkinson's disease.
Nomura T; Inoue Y; Nakashima K
J Neurol Sci; 2006 Dec; 250(1-2):39-44. PubMed ID: 16899256
[TBL] [Abstract][Full Text] [Related]
10. Delta opioid receptors stimulation with [D-Ala2, D-Leu5] enkephalin does not provide neuroprotection in the hippocampus in rats subjected to forebrain ischemia.
Iwata M; Inoue S; Kawaguchi M; Kurita N; Horiuchi T; Nakamura M; Konishi N; Furuya H
Neurosci Lett; 2007 Mar; 414(3):242-6. PubMed ID: 17207574
[TBL] [Abstract][Full Text] [Related]
11. Restless legs syndrome: pathophysiology and the role of iron and folate.
Patrick LR
Altern Med Rev; 2007 Jun; 12(2):101-12. PubMed ID: 17604457
[TBL] [Abstract][Full Text] [Related]
12. Novel imine antioxidants at low nanomolar concentrations protect dopaminergic cells from oxidative neurotoxicity.
Hajieva P; Mocko JB; Moosmann B; Behl C
J Neurochem; 2009 Jul; 110(1):118-32. PubMed ID: 19486265
[TBL] [Abstract][Full Text] [Related]
13. Effect of centrophenoxine against rotenone-induced oxidative stress in an animal model of Parkinson's disease.
Verma R; Nehru B
Neurochem Int; 2009 Nov; 55(6):369-75. PubMed ID: 19375462
[TBL] [Abstract][Full Text] [Related]
14. Down-regulation of alpha-synuclein expression can rescue dopaminergic cells from cell death in the substantia nigra of Parkinson's disease rat model.
Hayashita-Kinoh H; Yamada M; Yokota T; Mizuno Y; Mochizuki H
Biochem Biophys Res Commun; 2006 Mar; 341(4):1088-95. PubMed ID: 16460685
[TBL] [Abstract][Full Text] [Related]
15. Treatment with delta opioid peptide enhances in vitro and in vivo survival of rat dopaminergic neurons.
Borlongan CV; Su TP; Wang Y
Neuroreport; 2000 Apr; 11(5):923-6. PubMed ID: 10790856
[TBL] [Abstract][Full Text] [Related]
16. Neuroprotective effects of iron chelator Desferal on dopaminergic neurons in the substantia nigra of rats with iron-overload.
Jiang H; Luan Z; Wang J; Xie J
Neurochem Int; 2006 Nov; 49(6):605-9. PubMed ID: 16806586
[TBL] [Abstract][Full Text] [Related]
17. Molecular hydrogen is protective against 6-hydroxydopamine-induced nigrostriatal degeneration in a rat model of Parkinson's disease.
Fu Y; Ito M; Fujita Y; Ito M; Ichihara M; Masuda A; Suzuki Y; Maesawa S; Kajita Y; Hirayama M; Ohsawa I; Ohta S; Ohno K
Neurosci Lett; 2009 Apr; 453(2):81-5. PubMed ID: 19356598
[TBL] [Abstract][Full Text] [Related]
18. Mitochondrial ERK plays a key role in δ-opioid receptor neuroprotection against acute mitochondrial dysfunction.
Zhu M; Li M; Yang F; Ou X; Ren Q; Gao H; Zhu C; Guo J
Neurochem Int; 2011 Nov; 59(6):739-48. PubMed ID: 21864608
[TBL] [Abstract][Full Text] [Related]
19. Delta opioid peptide [D-Ala2,D-leu5]enkephalin blocks the long-term loss of dopamine transporters induced by multiple administrations of methamphetamine: involvement of opioid receptors and reactive oxygen species.
Tsao LI; Ladenheim B; Andrews AM; Chiueh CC; Cadet JL; Su TP
J Pharmacol Exp Ther; 1998 Oct; 287(1):322-31. PubMed ID: 9765353
[TBL] [Abstract][Full Text] [Related]
20. Neuroprotective effect of the natural iron chelator, phytic acid in a cell culture model of Parkinson's disease.
Xu Q; Kanthasamy AG; Reddy MB
Toxicology; 2008 Mar; 245(1-2):101-8. PubMed ID: 18255213
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
